ENSYSCE BIOSCIENCES INC (ENSC)
US2936024056 - Common Stock
Taking everything into account, ENSC scores 3 out of 10 in our fundamental rating. ENSC was compared to 568 industry peers in the Biotechnology industry. The financial health of ENSC is average, but there are quite some concerns on its profitability. While showing a medium growth rate, ENSC is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year ENSC has reported negative net income.
ENSC had a negative operating cash flow in the past year.
In multiple years ENSC reported negative net income over the last 5 years.
ENSC had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
ENSC has a Return On Assets of -84.47%. This is in the lower half of the industry: ENSC underperforms 70.80% of its industry peers.
The Return On Equity of ENSC (-114.75%) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -84.47% | ||
| ROE | -114.75% | ||
| ROIC | N/A |
ROA(3y)-333.3%
ROA(5y)-193.26%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ENSC does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
ENSC does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ENSC has more shares outstanding
The number of shares outstanding for ENSC has been reduced compared to 5 years ago.
ENSC has a better debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of -17.79, we must say that ENSC is in the distress zone and has some risk of bankruptcy.
ENSC's Altman-Z score of -17.79 is on the low side compared to the rest of the industry. ENSC is outperformed by 84.96% of its industry peers.
There is no outstanding debt for ENSC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -17.79 |
ROIC/WACCN/A
WACC9.16%
2.3 Liquidity
A Current Ratio of 3.24 indicates that ENSC has no problem at all paying its short term obligations.
ENSC has a Current ratio of 3.24. This is in the lower half of the industry: ENSC underperforms 60.53% of its industry peers.
ENSC has a Quick Ratio of 3.24. This indicates that ENSC is financially healthy and has no problem in meeting its short term obligations.
ENSC has a Quick ratio of 3.24. This is comparable to the rest of the industry: ENSC outperforms 40.88% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.24 | ||
| Quick Ratio | 3.24 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 90.66% over the past year.
Looking at the last year, ENSC shows a very strong growth in Revenue. The Revenue has grown by 40.36%.
EPS 1Y (TTM)90.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%108.05%
Revenue 1Y (TTM)40.36%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%685.29%
3.2 Future
The Earnings Per Share is expected to grow by 163.16% on average over the next years. This is a very strong growth
ENSC is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 157.05% yearly.
EPS Next Y-139.6%
EPS Next 2Y-56.65%
EPS Next 3Y163.16%
EPS Next 5YN/A
Revenue Next Year22.5%
Revenue Next 2Y-41.42%
Revenue Next 3Y186.08%
Revenue Next 5Y157.05%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for ENSC. In the last year negative earnings were reported.
Also next year ENSC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
ENSC's earnings are expected to grow with 163.16% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-56.65%
EPS Next 3Y163.16%
5. Dividend
5.1 Amount
ENSC does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ENSYSCE BIOSCIENCES INC
NASDAQ:ENSC (12/20/2024, 8:07:14 PM)
After market: 7.775 -0.32 (-4.01%)8.1
+0.15 (+1.89%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners4.41%
Inst Owner Change477.23%
Ins Owners1.54%
Ins Owner Change0%
Market Cap8.02M
Analysts82.86
Price TargetN/A
Short Float %N/A
Short Ratio0.05
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)83.98%
Min EPS beat(2)44.7%
Max EPS beat(2)123.26%
EPS beat(4)3
Avg EPS beat(4)38.42%
Min EPS beat(4)-54.38%
Max EPS beat(4)123.26%
EPS beat(8)7
Avg EPS beat(8)41.95%
EPS beat(12)9
Avg EPS beat(12)-139.01%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)600.1%
Min Revenue beat(2)-40.59%
Max Revenue beat(2)1240.78%
Revenue beat(4)2
Avg Revenue beat(4)300.74%
Min Revenue beat(4)-40.59%
Max Revenue beat(4)1240.78%
Revenue beat(8)2
Avg Revenue beat(8)138.2%
Revenue beat(12)3
Avg Revenue beat(12)80.28%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-18.07%
PT rev (3m)-46.14%
EPS NQ rev (1m)35.71%
EPS NQ rev (3m)44.62%
EPS NY rev (1m)-770.63%
EPS NY rev (3m)-770.63%
Revenue NQ rev (1m)2.04%
Revenue NQ rev (3m)-15.25%
Revenue NY rev (1m)133.33%
Revenue NY rev (3m)133.33%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 1.81 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.16 | ||
| P/tB | 1.16 | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.07
EYN/A
EPS(NY)-13
Fwd EYN/A
FCF(TTM)-8.62
FCFYN/A
OCF(TTM)-8.62
OCFYN/A
SpS4.47
BVpS6.98
TBVpS6.98
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -84.47% | ||
| ROE | -114.75% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-333.3%
ROA(5y)-193.26%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.47
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.24 | ||
| Quick Ratio | 3.24 | ||
| Altman-Z | -17.79 |
F-Score4
WACC9.16%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)90.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%108.05%
EPS Next Y-139.6%
EPS Next 2Y-56.65%
EPS Next 3Y163.16%
EPS Next 5YN/A
Revenue 1Y (TTM)40.36%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%685.29%
Revenue Next Year22.5%
Revenue Next 2Y-41.42%
Revenue Next 3Y186.08%
Revenue Next 5Y157.05%
EBIT growth 1Y54.18%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-81.5%
EBIT Next 3Y-2.26%
EBIT Next 5Y31.23%
FCF growth 1Y53.49%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y53.49%
OCF growth 3YN/A
OCF growth 5YN/A